| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| General and administrative | 1,754,856 | |||
| Research and development | 158,699 | |||
| Total operating expenses | 1,913,555 | |||
| Loss from operations | -1,913,555 | |||
| Interest income | 5,111 | |||
| Other income | 4,260 | |||
| Total other income | 9,371 | |||
| Net loss | -1,904,184 | |||
| Net loss per share attributable to common stockholders, basic | -0.07 | |||
| Net loss per share attributable to common stockholders, diluted | -0.07 | |||
| Weighted-average common shares outstanding, basic | 27,975,207 | |||
| Weighted-average common shares outstanding, diluted | 27,975,207 | |||
Turn Therapeutics Inc. (TTRX)
Turn Therapeutics Inc. (TTRX)